Proteus vulgaris Response to Various Antibacterial Agents
Proteus vulgaris Antibacterial Response
DOI:
https://doi.org/10.54393/fbt.v1i02.9Keywords:
Proteus vulgaris, Antibiotics, Gram Negative Bacteria, PatientsAbstract
Proteus vulgaris is commonly associated with urinary tract infections, wound infections and sepsis. The ability of microorganisms to resist antibiotic actions is referred to as antibiotic resistance. Objective: To compare the antibacterial effects of various medications on clinical isolates of P. vulgaris was the goal. Methods: Over the course of a year, 1000 samples were collected in a cross-sectional study at a hospital in Lahore, Pakistan. The Kirby-Bauer disc diffusion technique was used to test for antibiotic susceptibility. Results: It was determined that the most efficient antibacterial medicines against P. vulgaris. were Imipenem, Gentamycin, Amikacin, Augmentin, Linezolid, Levofloxacin, Ceftazidime, Norfloxacine, and Cefazolin. On the other hand, Meropenem, Cephalothin, Rifampicin, Cefoxitin, and Ampicillin had little effect on Proteus vulgaris. Conclusions: The study emphasizes the significance of preventative measures, such as responsible antibiotic use, the development of novel treatments, and the application of infection control techniques in healthcare settings, to effectively manage and prevent the spread of resistance. Antibiotic resistance in P. vulgaris is becoming a growing cause for concern.
References
Turkoglu A, Duru ME, Mercan N, Kivrak I, Gezer K. Antioxidant and antimicrobial activities of Laetiporus sulphureus (Bull.) Murrill. Food Chemistry. 2007 Jan; 101(1): 267-73. doi: 10.1016/j.foodchem.2006.01.025
Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. Journal of Antimicrobial Chemotherapy. 2007 Oct; 60(4): 788-94. doi: 10.1093/jac/dkm258
de Azavedo JC, McGavin M, Duncan C, Low DE, McGeer A. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrobial Agents and Chemotherapy. 2001 Dec; 45(12): 3504-8. doi: 10.1128/AAC.45.12.3504-3508.2001
Haq FU, Imran M, Saleem S, Aftab U, Ghazal A. Investigation of Morchella esculenta and Morchella conica for their antibacterial potential against methicillin-susceptible Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Streptococcus pyogenes. Archives of Microbiology. 2022 July; 204(7): 1-13. doi: 10.1007/s00203-022-03003-8
Aberkane S, Compain F, Decré D, Dupont C, Laurens C, Vittecoq M, et al. High prevalence of SXT/R391-related integrative and conjugative elements carrying bla CMY-2 in Proteus mirabilis isolates from gulls in the south of France. Antimicrobial Agents and Chemotherapy. 2016 Feb; 60(2): 1148-52. doi: 10.1128/AAC.01654-15
Kaleem F, Usman J, Hassan A, Omair M, Khalid A, Uddin R. Sensitivity pattern of methicillin resistant Staphylococcus aureus isolatedfrom patients admitted in a tertiary care hospital of Pakistan. Iranian Journal of Microbiology. 2010; 2(3): 141-3.
Walsh TR. Emerging carbapenemases: a global perspective. International journal of antimicrobial agents. 2010 Nov; 36: S8-14. doi: 10.1016/S0924-8579(10)70004-2
Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. MBio. 2018 Mar; 9(1): e00105-18. doi: 10.1128/mBio.00105-18
Siegel RE. Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respiratory Care. 2008 Apr; 53(4): 471-9.
Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 2008 Mar; 52(3): 813-21. doi: 10.1128/AAC.01169-07
Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. The American Journal of Clinical Nutrition. 2001 Dec; 74(6): 833-9. doi: 10.1093/ajcn/74.6.833
Slama TG. Gram-negative antibiotic resistance: there is a price to pay. Critical Care. 2008 May; 12: 1-7. doi: 10.1186/cc6817
Chopra I, Schofield C, Everett M, O'Neill A, Miller K, Wilcox M, et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. The Lancet Infectious Diseases. 2008 Feb; 8(2): 133-9. doi: 10.1016/S1473-3099(08)70018-5
Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. Journal of Infectious Diseases. 1999 Dec; 180(6): 1950-6. doi: 10.1086/315109
Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Reviews of Infectious Diseases. 1990 Sep; 12(5): 856-72. doi: 10.1093/clinids/12.5.856
Biendo M, Thomas D, Laurans G, Hamdad-Daoudi F, Canarelli B, Rousseau F, et al. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum β-lactamases in a French university hospital. Clinical Microbiology and Infection. 2005 May; 11(5): 395-401.doi: 10.1111/j.1469-0691.2005.01147.x
Alabi OS, Mendonça N, Adeleke OE, da Silva GJ. Molecular screening of antibiotic-resistant determinants among multidrug-resistant clinical isolates of Proteus mirabilis from SouthWest Nigeria. African Health Sciences. 2017 Jul; 17(2): 356-65. doi: 10.4314/ahs.v17i2.9
Reid G and Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes and Infection. 2002 Mar; 4(3): 319-24. doi: 10.1016/S1286-4579(02)01544-7
d’Oliveira REC, Barros RR, Mendonça CRV, Teixeira LM, Castro ACD. Susceptibility to antimicrobials and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae from Rio de Janeiro, Brazil. Journal of Medical Microbiology. 2003 Nov; 52(11): 1029–30. doi: 10.1099/jmm.0.05278-0
Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care. 2006 Jun; 10(3): 1-7. doi: 10.1186/cc4934
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Futuristic Biotechnology
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments editor@fbtjournal.com
